1
|
Liu X, Huang R, Wan J. Puerarin: a potential natural neuroprotective agent for neurological disorders. Biomed Pharmacother 2023; 162:114581. [PMID: 36966665 DOI: 10.1016/j.biopha.2023.114581] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 03/18/2023] [Accepted: 03/21/2023] [Indexed: 03/30/2023] Open
Abstract
Puerarin is an isoflavone compound derived from Pueraria lobata in traditional Chinese medicine. Accumulating evidence has indicated that puerarin demonstrates multiple pharmacological effects and exhibits treatment potential for various neurological disorders. Based on the latest research progress on puerarin as a neuroprotective agent, its pharmacological activity, molecular mechanism, and therapeutic application were systematically reviewed with emphasis on pre-clinical studies. The related information was extracted and compiled from major scientific databases, including PubMed, ScienceDirect, SpringerLink, and Chinese National Knowledge Infrastructure, using 'Puerarin', 'Neuroprotection', 'Apoptosis', 'Autophagy', 'Antioxidant', 'Mitochondria', 'Anti-inflammation' as keywords. This review complied with The Preferred Reporting Items for Systematic Reviews criteria. Forty-three articles met established inclusion and exclusion criteria. Puerarin has shown neuroprotective effects against a variety of neurological disorders, including ischemic cerebrovascular disease, subarachnoid hemorrhage, epilepsy, cognitive disorders, traumatic brain injury, Parkinson's disease, Alzheimer's disease, anxiety, depression, diabetic neuropathy, and neuroblastoma/glioblastoma. Puerarin demonstrates anti-apoptosis, proinflammatory mediator inhibitory, autophagy regulatory, anti-oxidative stress, mitochondria protection, Ca2+ influx inhibitory, and anti-neurodegenerative activities. Puerarin exerts noticeable neuroprotective effects on various models of neurological disorders in vivo (animal). This review will contribute to the development of puerarin as a novel clinical drug candidate for the treatment of neurological disorders. However, well-designed, high-quality, large-scale, multicenter randomized clinical studies are needed to determine the safety and clinical utility of puerarin in patients with neurological disorders.
Collapse
Affiliation(s)
- Xue Liu
- Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
| | - Rui Huang
- Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
| | - Jiye Wan
- Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
| |
Collapse
|
2
|
Yin P, Han X, Yu L, Zhou H, Yang J, Chen Y, Zhang T, Wan H. Pharmacokinetic analysis for simultaneous quantification of Saikosaponin A- paeoniflorin in normal and poststroke depression rats: A comparative study. J Pharm Biomed Anal 2023; 233:115485. [PMID: 37267872 DOI: 10.1016/j.jpba.2023.115485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 05/04/2023] [Accepted: 05/23/2023] [Indexed: 06/04/2023]
Abstract
Bupleurum and Paeonia are common compatibilities for the treatment of depression, most of which are used in classical prescriptions. The main active ingredients saikosaponin A (SSA) and paeoniflorin (PF) have significant therapeutic effects on poststroke depression (PSD). However, the pharmacokinetic (PK) behavior based on the combination of the two components has not been reported in rats. The aim of this study was to compare the pharmacokinetic characteristics of combined administration of SSA and PF in normal and PSD rats. Plasma samples were collected after SSA and PF were injected into the rat tail vein, and plasma pretreatments were analyzed by HPLC. Based on the concentration levels of SSA and PF in plasma, Drug and Statistics 3.2.6 (DAS 3.2.6) software was used to establish the blood drug concentration model. PK data showed that compared with the normal rats, the values of related parameters t1/2α, AUC(0-t), AUC(0-∞) were decreased in diseased rats, while the values of CL1 was increased. These findings suggest that PSD can significantly affect the PK parameters of SSA-PF. This study established a PK model to explore the time-effect relationship, in order to provide experimental and theoretical support for clinical application.
Collapse
Affiliation(s)
- Ping Yin
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Xi Han
- School of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Li Yu
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Huifen Zhou
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Jiehong Yang
- School of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Ying Chen
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Ting Zhang
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
| | - Haitong Wan
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
| |
Collapse
|
3
|
Meng F, Guo B, Ma YQ, Li KW, Niu FJ. Puerarin: A review of its mechanisms of action and clinical studies in ophthalmology. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 107:154465. [PMID: 36166943 DOI: 10.1016/j.phymed.2022.154465] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Revised: 09/07/2022] [Accepted: 09/18/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Pueraria is the common name of the dried root of either Pueraria montana var. lobata (Willd.) Maesen & S.M.Almeida ex Sanjappa & Predeep (syn. Pueraria lobata (Willd.) Ohwi) or Pueraria montana var. thomsonii (Benth.) M.R.Almeida (syn. Pueraria thomsonii Benth.). Puerarin is a C-glucoside of the isoflavone daidzein extracted from Pueraria. It has been widely investigated to explore its therapeutic role in eye diseases and the molecular mechanisms. PURPOSE To collect the available literature from 2000 to 2022 on puerarin in the treatment of ocular diseases and suggest the future required directions to improve its medicinal value. METHOD The content of this review was obtained from databases such as Web of Science, PubMed, Google Scholar, China National Knowledge Infrastructure (CNKI), and the Wanfang Database. RESULTS The search yielded 428 articles, of which 159 articles were included after excluding duplicate articles and articles related to puerarin but less relevant to the topic of the review. In eleven articles, the bioavailability of puerarin was discussed. Despite puerarin possesses diverse biological activities, its bioavailability on its own is poor. There are 95 articles in which the therapeutic mechanisms of puerarin in ocular diseases was reported. Of these, 54 articles discussed the various signalling pathways related to occular diseases affected by puerarin. The other 41 articles discussed specific biological activities of puerarin. It plays a therapeutic role in ophthalmopathy via regulating nuclear factor kappa-B (NF-ĸB), mitogen-activated protein kinases (MAPKs), PI3K/AKT, JAK/STAT, protein kinase C (PKC) and other related pathways, affecting the expression of tumour necrosis factor α (TNF-α), interleukin-1β (IL-1β), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), superoxide dismutase (SOD), B-cell lymphoma-2 (Bcl-2) and other cytokines resulting in anti-inflammatory, antioxidant and anti-apoptotic effects. The clinical applications of puerarin in ophthalmology were discussed in 25 articles. Eleven articles discussed the toxicity of puerarin. The literature suggests that puerarin has a good curative effect and can be used safely in clinical practice. CONCLUSION This review has illustrated the diverse applications of puerarin acting on ocular diseases and suggested that puerarin can be used for treating diabetic retinopathy, retinal vascular occlusion, glaucoma and other ocular diseases in the clinic. Some ocular diseases are the result of the combined action of multiple factors, and the effect of puerarin on different factors needs to be further studied to improve a more complete mechanism of action of puerarin. In addition, it is necessary to increase the number of subjects in clinical trials and conduct clinical trials for other ocular diseases. The information presented here will guide future research studies.
Collapse
Affiliation(s)
- Fan Meng
- Shandong University of Traditional Chinese Medicine, Daxue Road 4655, Ji'nan 250355, China
| | - Bin Guo
- Shandong University of Traditional Chinese Medicine, Daxue Road 4655, Ji'nan 250355, China
| | - Yi-Qing Ma
- Shandong University of Traditional Chinese Medicine, Daxue Road 4655, Ji'nan 250355, China
| | - Kun-Wei Li
- Shandong University of Traditional Chinese Medicine, Daxue Road 4655, Ji'nan 250355, China.
| | - Feng-Ju Niu
- Shandong University of Traditional Chinese Medicine, Daxue Road 4655, Ji'nan 250355, China.
| |
Collapse
|
4
|
Jiang L, Xiong Y, Tu Y, Zhang W, Zhang Q, Nie P, Yan X, Liu H, Liu R, Xu G. Elucidation of the Transport Mechanism of Puerarin and Gastrodin and Their Interaction on the Absorption in a Caco-2 Cell Monolayer Model. Molecules 2022; 27:molecules27041230. [PMID: 35209020 PMCID: PMC8875129 DOI: 10.3390/molecules27041230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Revised: 02/06/2022] [Accepted: 02/07/2022] [Indexed: 02/04/2023] Open
Abstract
Puerarin (PUR) and gastrodin (GAS) are often used in combined way for treating diseases caused by microcirculation disorders. The current study aimed to investigate the absorption and transportation mechanism of PUR and GAS and their interaction via Caco-2 monolayer cell model. In this work, the concentration in Caco-2 cell of PUR and GAS was determined by HPLC method. The bidirectional transport of PUR and GAS and the inhibition of drug efflux including verapamil and cyclosporine on the transport of these two components were studied. The mutual influence between PUR and GAS, especially the effect of the latter on the former of the bidirectional transport were also investigated. The transport of 50 μg·mL−1 PUR in Caco-2 cells has no obvious directionality. While the transport of 100 and 200 μg·mL−1 PUR presents a strong directionality, and this directionality can be inhibited by verapamil and cyclosporine. When PUR and GAS were used in combination, GAS could increase the absorption of PUR while PUR had no obvious influence on GAS. Therefore, the compatibility of PUR and GAS is reasonable, and GAS can promote the transmembrane transport of PUR, the effect of which is similar to that of verapamil.
Collapse
Affiliation(s)
- Li Jiang
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
- Jiangxi Provincial Key Laboratory of TCM Etiopathogenesis, Jiangxi University of Chinese Medicine, Nanchang 330004, China
- Key Laboratory of Pharmacology of Traditional Chinese Medicine in Jiangxi, Nanchang 330004, China
| | - Yanling Xiong
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, China;
| | - Yu Tu
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
| | - Wentong Zhang
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
| | - Qiyun Zhang
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
- Jiangxi Provincial Key Laboratory of TCM Etiopathogenesis, Jiangxi University of Chinese Medicine, Nanchang 330004, China
| | - Peng Nie
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
- Jiangxi Provincial Key Laboratory of TCM Etiopathogenesis, Jiangxi University of Chinese Medicine, Nanchang 330004, China
| | - Xiaojun Yan
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
- Jiangxi Provincial Key Laboratory of TCM Etiopathogenesis, Jiangxi University of Chinese Medicine, Nanchang 330004, China
| | - Hongning Liu
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
- Jiangxi Provincial Key Laboratory of TCM Etiopathogenesis, Jiangxi University of Chinese Medicine, Nanchang 330004, China
| | - Ronghua Liu
- Department of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330004, China;
| | - Guoliang Xu
- Center for Differentiation and Development of TCM Basic Theory, Jiangxi University of Chinese Medicine, Nanchang 330004, China; (L.J.); (Y.T.); (W.Z.); (Q.Z.); (P.N.); (X.Y.); (H.L.)
- Jiangxi Provincial Key Laboratory of TCM Etiopathogenesis, Jiangxi University of Chinese Medicine, Nanchang 330004, China
- Key Laboratory of Pharmacology of Traditional Chinese Medicine in Jiangxi, Nanchang 330004, China
- Correspondence:
| |
Collapse
|
5
|
Prasain JK, Barnes S, Wyss JM. Kudzu isoflavone C‐glycosides: Analysis, biological activities, and metabolism. FOOD FRONTIERS 2021. [DOI: 10.1002/fft2.105] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Affiliation(s)
- Jeevan K. Prasain
- Departments of Pharmacology and Toxicology University of Alabama Birmingham Alabama United States
| | - Stephen Barnes
- Departments of Pharmacology and Toxicology University of Alabama Birmingham Alabama United States
| | - J. Michael Wyss
- Department of Cell Development and Integrative Biology University of Alabama Birmingham Alabama United States
| |
Collapse
|
6
|
Sabiu S, Idowu K. An insight on the nature of biochemical interactions between glycyrrhizin, myricetin and CYP3A4 isoform. J Food Biochem 2021; 46:e13831. [PMID: 34164820 DOI: 10.1111/jfbc.13831] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 05/23/2021] [Accepted: 06/07/2021] [Indexed: 12/13/2022]
Abstract
Drug interaction studies are imperative to gain insights into the beneficial or harmful effects of therapeutic and dietary agents. This study investigated the mechanism of modulatory roles of glycyrrhizin (GLH) and myricetin (MYC) on the human CYP3A4 isoform using in silico and in vitro methods. While MYC had concentration-dependent inhibitory effect on CYP3A4 (IC50 : 10.5 ± 0.55 μM) with characteristic Km and Vmax values of 1.13 μM and 1.54 nM/min, respectively, GLH exhibited no inhibitory effect on CYP3A4 activity in vitro. These observations are consistent with the results of in silico evaluations where the effect of MYC compared well with that of ketoconazole (a known CYP3A4 inhibitor) against CYP3A4. Overall, the established interactions between the study compounds and CYP3A4 could potentiate clinically vital drug-drug interactions and has lent credence to the mechanism of modulatory effect of MYC and GLH on CYP3A4 that could guide their safe use as therapeutic agents. PRACTICAL IMPLICATIONS: Myricetin (MYR) and glycyrrhizin (GLH) occur freely in commonly ingested foods and their supplements are recommended for the treatment of several debilitating diseases such as diabetes, cancer, and cardiovascular complications. This study provided an insight on the possible interactions that could be established between these compounds (MYR and GLH) and CYP3A4 when ingested and metabolized by the liver. The results suggested possibilities of potential clinical drug-drug interactions and advocates for their cautious use within the therapeutic dose in food supplements or medications to avoid probable liver damage.
Collapse
Affiliation(s)
- Saheed Sabiu
- Department of Biotechnology and Food Technology, Faculty of Applied Sciences, Durban University of Technology, Durban, South Africa
| | - Kehinde Idowu
- School of Laboratory Medicine and Medical Sciences, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
| |
Collapse
|
7
|
Cheng Z, Li Y, Zhu X, Wang K, Ali Y, Shu W, Zhang T, Zhu L, Murray M, Zhou F. The Potential Application of Pentacyclic Triterpenoids in the Prevention and Treatment of Retinal Diseases. PLANTA MEDICA 2021; 87:511-527. [PMID: 33761574 DOI: 10.1055/a-1377-2596] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Retinal diseases are a leading cause of impaired vision and blindness but some lack effective treatments. New therapies are required urgently to better manage retinal diseases. Natural pentacyclic triterpenoids and their derivatives have a wide range of activities, including antioxidative, anti-inflammatory, cytoprotective, neuroprotective, and antiangiogenic properties. Pentacyclic triterpenoids have great potential in preventing and/or treating retinal pathologies. The pharmacological effects of pentacyclic triterpenoids are often mediated through the modulation of signalling pathways, including nuclear factor erythroid-2 related factor 2, high-mobility group box protein 1, 11β-hydroxysteroid dehydrogenase type 1, and Src homology region 2 domain-containing phosphatase-1. This review summarizes recent in vitro and in vivo evidence for the pharmacological potential of pentacyclic triterpenoids in the prevention and treatment of retinal diseases. The present literature supports the further development of pentacyclic triterpenoids. Future research should now attempt to improve the efficacy and pharmacokinetic behaviour of the agents, possibly by the use of medicinal chemistry and targeted drug delivery strategies.
Collapse
Affiliation(s)
- Zhengqi Cheng
- Sydney Pharmacy School, The University of Sydney, Camperdown, Australia
| | - Yue Li
- Sydney Pharmacy School, The University of Sydney, Camperdown, Australia
| | - Xue Zhu
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China
| | - Ke Wang
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China
| | - Youmna Ali
- Sydney Pharmacy School, The University of Sydney, Camperdown, Australia
| | - Wenying Shu
- Department of Pharmacy, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong Province, China
| | - Ting Zhang
- Save Sight Institute, The University of Sydney, Sydney, Australia
| | - Ling Zhu
- Save Sight Institute, The University of Sydney, Sydney, Australia
| | - Michael Murray
- Discipline of Pharmacology, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia
| | - Fanfan Zhou
- Sydney Pharmacy School, The University of Sydney, Camperdown, Australia
| |
Collapse
|
8
|
Wang H, Dong L, Qu F, He H, Sun W, Man Y, Jiang H. Effects of glycyrrhizin on the pharmacokinetics of nobiletin in rats and its potential mechanism. PHARMACEUTICAL BIOLOGY 2020; 58:352-356. [PMID: 32298152 PMCID: PMC7178892 DOI: 10.1080/13880209.2020.1751661] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Context: Both nobiletin (NBL) and glycyrrhizin (GL) have anti-inflammatory and antitumor properties. These agents may be co-administered in the clinic. However, the drug-drug interaction between them is not clear.Objective: The drug-drug interaction between GL and NBL was investigated, to clarify the effect of GL on the pharmacokinetics of NBL, and its main mechanism.Materials and methods: The pharmacokinetic profiles of oral administration of NBL (50 mg/kg) in Sprague-Dawley rats of two groups with six each, with or without pre-treatment of GL (100 mg/kg/day for 7 days), were investigated. The effects of GL on the metabolic stability and transport of NBL were also investigated through the rat liver microsome and Caco-2 cell transwell models.Results: The results showed that GL significantly decreased the peak plasma concentration (from 1.74 ± 0.15 to 1.12 ± 0.10 μg/mL) and the t1/2 (7.44 ± 0.65 vs. 5.92 ± 0.68) of NBL, and the intrinsic clearance rate of NBL was increased by the pre-treatment with GL (39.49 ± 2.5 vs. 48.29 ± 3.4 μL/min/mg protein). The Caco-2 cell transwell experiments indicated that GL could increase the efflux ratio of NBL from 1.61 to 2.41.Discussion and conclusion: These results indicated that GL could change the pharmacokinetic profile of NBL, via increasing the metabolism and efflux of NBL in rats. It also suggested that the dose of NBL should be adjusted when co-administrated with GL in the clinic.
Collapse
Affiliation(s)
- Hao Wang
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Lin Dong
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Fangfei Qu
- Department of Special Inspection, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Huimin He
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Wei Sun
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
| | - Yuqing Man
- Department of Pharmacy, Binzhou Medical University Hospital, Binzhou, Shandong, China
| | - Hongjie Jiang
- Department of Pediatrics, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China
- CONTACT Hongjie Jiang Department of Pediatrics, Yantai Affiliated Hospital of Binzhou Medical University, No. 717, Jinbu Street, Yantai, Shandong, 264100, China
| |
Collapse
|
9
|
Zhang G, Ji J, Sun M, Ji Y, Ji H. Comparative Pharmacokinetic Profiles of Puerarin in Rat Plasma by UHPLC-MS/MS after Oral Administration of Pueraria lobata Extract and Pure Puerarin. JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY 2020; 2020:4258156. [PMID: 32351754 PMCID: PMC7178524 DOI: 10.1155/2020/4258156] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 03/16/2020] [Accepted: 03/25/2020] [Indexed: 06/11/2023]
Abstract
Puerarin is the main biologically active isoflavone in Pueraria lobata and has a wide range of biological activities. However, due to its poor water solubility and low oral bioavailability, its clinical applications are restricted. Compared with puerarin, the Pueraria lobata extract (PLE) has better water solubility, lower toxicity, and less side effects. In this study, the pharmacokinetics of orally administered puerarin (100 mg/kg) and PLE (763 mg/kg, equivalent to 100.0 mg/kg of puerarin) to rats was investigated by the UHPLC-MS/MS method. Results showed that when the rats were administered PLE, the area under the concentration-time curve from zero to infinity (AUC 0-inf ) dramatically increased from 219.83 ± 64.37 μg h/L to 462.62 ± 51.74 μg h/L (p < 0.01). The elimination half-time (t 1/2 ) also increased from 1.60 ± 0.38 h to 12.04 ± 5.10 h (p < 0.01). The maximum concentration (C max) of puerarin decreased from 101.64 ± 41.82 ng/mL to 48.64 ± 21.47 ng/mL (p < 0.01), and time to reach the maximum plasma concentration (T max) of puerarin decreased from 1.46 ± 1.08 h to 0.54 ± 0.30 h (p < 0.01). Results indicated that the pharmacokinetics of puerarin in Pueraria lobata may be dramatically different from pure puerarin in the plasma of rat, and oral bioavailability of puerarin may be increased when PLE was administrated to rats.
Collapse
Affiliation(s)
- Guozhe Zhang
- Department of Translational Medicine, Jiangsu Vocational College of Medicine, 283 South of Republic Road, Yancheng 224005, China
| | - Jianwei Ji
- Department of Pharmacy, Yancheng Third People's Hospital, 2 West of Xindu Road, Yancheng 224001, China
| | - Mingzhong Sun
- Department of Pharmacy, Yancheng Third People's Hospital, 2 West of Xindu Road, Yancheng 224001, China
| | - Yuqiao Ji
- Department of Pharmacy, Yancheng Third People's Hospital, 2 West of Xindu Road, Yancheng 224001, China
| | - Hongjian Ji
- Department of Pharmacy, Yancheng Third People's Hospital, 2 West of Xindu Road, Yancheng 224001, China
- Department of Pharmacy, Nanjing University of Chinese Medicine, Xianlin Road 138, Nanjing 210023, China
| |
Collapse
|
10
|
Wang Q, Wu Y, Xiang F, Feng Y, Li Z, Ding Y. Effects of puerarin on the pharmacokinetics of triptolide in rats. PHARMACEUTICAL BIOLOGY 2019; 57:407-411. [PMID: 31230510 PMCID: PMC6598480 DOI: 10.1080/13880209.2019.1626448] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Context: Puerarin and triptolide are sometimes used together for the treatment of disease in Chinese clinics; however, the drug-drug interaction between puerarin and triptolide is still unknown. Objective: This study investigates the effects of puerarin on the pharmacokinetics of triptolide in rats and clarifies its main mechanism. Materials and methods: The pharmacokinetic profiles of oral administration of triptolide (1 mg/kg) in Sprague-Dawley rats with (test group, n = 6) or without pretreatment (control group, n = 6) with puerarin (100 mg/kg/day for seven days) were investigated. The effects of puerarin on the transport and metabolic stability of triptolide were also investigated using Caco-2 cell transwell model and rat liver microsomes. Results: The results showed that puerarin could significantly increase the peak plasma concentration (from 187.25 ± 15.36 to 219.67 ± 21.52 ng/mL), and decrease its oral clearance (from 4.92 ± 0.35 to 62.46 ± 3.75 ± 0.19 L/h/kg). The Caco-2 cell transwell experiments indicated that puerarin could decrease the efflux ratio of triptolide from 2.70 to 1.33, and the intrinsic clearance rate of triptolide was decreased by the pretreatment with puerarin (38.8 ± 4.7 vs. 32.9 ± 6.5 μL/min/mg protein). Discussion and conclusions: Puerarin could significantly change the pharmacokinetic profiles of triptolide in rats, and it might exert these effects through increasing the absorption of triptolide by inhibiting the activity of P-gp, or through inhibiting the metabolism of triptolide in rat liver. The results also showed that the dose of triptolide should be decreased when these drugs were co-administered.
Collapse
Affiliation(s)
- Qingfa Wang
- Department of Neonatology, Yidu Central Hospital of Weifang, Shandong, China
| | - Yanping Wu
- Department of Neonatology, Yidu Central Hospital of Weifang, Shandong, China
| | - Fengting Xiang
- Department of Neonatology, Yidu Central Hospital of Weifang, Shandong, China
| | - Yan Feng
- Department of Neonatology, Yidu Central Hospital of Weifang, Shandong, China
| | - Zhenghao Li
- Department of Neonatology, Yidu Central Hospital of Weifang, Shandong, China
| | - Yufeng Ding
- Department of Pharmacy, Yidu Central Hospital of Weifang, Shandong, China
- CONTACT Yufeng Ding Department of Pharmacy, Yidu Central Hospital of Weifang, No. 4138, South Linglongshan Road, Weifang262500, Shandong, China
| |
Collapse
|
11
|
Zhang L. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. Drug Deliv 2019; 26:860-869. [PMID: 31524010 PMCID: PMC6758605 DOI: 10.1080/10717544.2019.1660732] [Citation(s) in RCA: 82] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 08/22/2019] [Accepted: 08/23/2019] [Indexed: 02/06/2023] Open
Abstract
Pueraria lobata (Willd.) Ohwi is a medicinal and edible homologous plant with a long history in China. Puerarin, the main component isolated from the root of Pueraria lobata, possesses a wide range of pharmacological properties. Daidzein and glucuronides are the main metabolites of puerarin and are excreted in the urine and feces. As active substrates of P-gp, multidrug resistance-associated protein and multiple metabolic enzymes, the pharmacokinetics of puerarin can be influenced by different pathological conditions and drug-drug interactions. Due to the poor water-solubility and liposolubility, the applications of puerarin are limited. So far, only puerarin injections and eye drops are on the market. Recent years, researches on improving the bioavailability of puerarin are developing rapidly, various nanotechnologies and preparation technologies including microemulsions and SMEDDS, dendrimers, nanoparticles and nanocrystals have been researched to improve the bioavailability of puerarin. In order to achieve biocompatibility and desired activity, more effective quality evaluations of nanocarriers are required. In this review, we summarize the pharmacokinetics and drug delivery systems of puerarin up to date.
Collapse
Affiliation(s)
- Liang Zhang
- College of Animal Pharmaceutical Sciences, Jiangsu Agri-animal Husbandry Vocational College, Taizhou, PR China
| |
Collapse
|
12
|
Sun H, Wang J, Lv J. Effects of glycyrrhizin on the pharmacokinetics of paeoniflorin in rats and its potential mechanism. PHARMACEUTICAL BIOLOGY 2019; 57:550-554. [PMID: 31429612 PMCID: PMC6713085 DOI: 10.1080/13880209.2019.1651876] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Context: Paeoniflorin is reported to possess numerous pharmacological activities. Paeoniflorin and glycyrrhizin are always used together for the treatment of disease in China clinics; however, the drug-drug interaction between glycyrrhizin and paeoniflorin is still unknown. Objective: This study investigates the effects of glycyrrhizin on the pharmacokinetics of paeoniflorin in rats. Materials and methods: The pharmacokinetics of orally administered paeoniflorin (20 mg/kg) with or without glycyrrhizin pre-treatment (at a dose of 100 mg/kg/day for 7 days) were investigated in male Sprague-Dawley rats using LC-MS/MS. Additionally, Caco-2 cell transwell model and rat liver microsome incubation experiments were also conducted to investigate its potential mechanism. Results: The results showed that when the rats were pre-treated with glycyrrhizin, the Cmax of paeoniflorin decreased from 59.57 ± 10.24 to 45.36 ± 8.61 ng/mL, and AUC0-inf also decreased from 282.02 ± 35.06 to 202.29 ± 28.28 μg·h/L. The t1/2 value of paeoniflorin decreased from 8.48 ± 2.01 to 5.88 ± 1.15 h (p < 0.05). The Caco-2 cell transwell experiments indicated that glycyrrhizin could increase the efflux ratio of paeoniflorin from 2.71 to 3.52, and the rat liver microsome incubation experiments showed that glycyrrhizin could significantly increase its intrinsic clearance rate from 53.7 ± 4.6 to 85.6 ± 7.1 μL/min/mg protein. Conclusions: These results indicated that glycyrrhizin could affect the pharmacokinetics of paeoniflorin, and it might work through decreasing the absorption of paeoniflorin by inducing the activity of P-gp or through increasing the clearance rate in rat liver by inducing the activity of CYP450 enzyme.
Collapse
Affiliation(s)
- Hongjuan Sun
- Department of Pediatrics, Liaocheng Dongchangfu People’s Hospital, Liaocheng, China
- CONTACT Hongjuan Sun Department of Pediatrics, Liaocheng Dongchangfu People’s Hospital, No. 128, Songgui Road, Liaocheng, Shandong 252004, China
| | - Jingfeng Wang
- Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
| | - Juan Lv
- Department of Pediatrics, Liaocheng Dongchangfu People’s Hospital, Liaocheng, China
| |
Collapse
|
13
|
Liu L, Li P, Qiao L, Li X. Effects of astragaloside IV on the pharmacokinetics of puerarin in rats. Xenobiotica 2019; 49:1173-1177. [PMID: 29790819 DOI: 10.1080/00498254.2018.1480819] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Lu Liu
- Department of Endocrinology, Seventh People’s Hospital of Shanghai University of TCM, Shanghai, China
| | - Pihong Li
- Department of General Surgery, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
| | - Lujun Qiao
- Department of ICU, Shengli Oilfield Central Hospital, Dongying, China
| | - Xiaohua Li
- Department of Endocrinology, Seventh People’s Hospital of Shanghai University of TCM, Shanghai, China
| |
Collapse
|
14
|
Zhou Y, Song X, Dong G. Effects of verapamil on the pharmacokinetics of puerarin in rats. Xenobiotica 2019; 49:1178-1182. [PMID: 30173622 DOI: 10.1080/00498254.2018.1518552] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Yun Zhou
- Department of Pharmacy, Yidu Central Hospital of Weifang, Shandong, China
| | - Xiaoli Song
- Department of Pharmacy, Yidu Central Hospital of Weifang, Shandong, China
| | - Gang Dong
- Department of Pharmacy, Yidu Central Hospital of Weifang, Shandong, China
| |
Collapse
|
15
|
He Y, Wang Z, Wu W, Xie Y, Wei Z, Yi X, Zeng Y, Li Y, Liu C. Identification of key transporters mediating uptake of aconitum alkaloids into the liver and kidneys and the potential mechanism of detoxification by active ingredients of liquorice. RSC Adv 2019; 9:16136-16146. [PMID: 35521419 PMCID: PMC9064382 DOI: 10.1039/c9ra00393b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Accepted: 05/08/2019] [Indexed: 11/23/2022] Open
Abstract
Aconite as a commonly used herb has been extensively applied in the treatment of rheumatoid arthritis, as pain relief, as well as for its cardiotonic actions. Aconitum alkaloids have been shown to be the most potent ingredients in aconite, in terms of efficacy against disease, but they are also highly toxic. Apart from neurological and cardiovascular toxicity exposed, the damage to hepatocytes and nephrocytes with long-term use of aconitum alkaloids should also be carefully considered. This study attempted to investigate the critical role of uptake transporters mediating the transport of aconitum alkaloids into the liver and the kidneys. The resulting data revealed that hOATP1B1, 1B3, hOCT1 and hOAT3 were mainly involved in the uptake of aconitum alkaloids. Additionally, the inhibitory effects of bioactive ingredients of liquorice on uptake transporters were screened and further confirmed by determining the IC50 values. The in vitro study suggested that liquorice might lower the toxicity of aconite by reducing its exposure in the liver and/or kidneys through inhibition of uptake transporters. Eventually, the in vivo study was indicative of detoxification of liquorice by decreasing the exposure of aconitine as representative compound in liver after co-administration, even though the exposure in kidney altered was less significant. In summary, hOATP1B1, 1B3, hOCT1 and hOCT3 were determined as the key uptake transporters mediating the transport process of aconitum alkaloids into the liver and/or kidneys, and liquorice may alleviate the toxicity caused by reduction of exposure through inhibition of those key uptake transporters.
Collapse
Affiliation(s)
- Yufei He
- Shenyang Pharmaceutical University No. 103 Wenhua Road, Shenhe District Shenyang City Liaoning Province China +86-22-23006860 +86-22-23006860
| | - Ze Wang
- Tianjin University of Traditional Chinese Medicine China
| | - Weidang Wu
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research 308, Anshan West Road, Nankai Tianjin China
| | - Ying Xie
- State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology Macau SAR China
| | - Zihong Wei
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research 308, Anshan West Road, Nankai Tianjin China
| | - Xiulin Yi
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research 308, Anshan West Road, Nankai Tianjin China
| | - Yong Zeng
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research 308, Anshan West Road, Nankai Tianjin China
| | - Yazhuo Li
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research 308, Anshan West Road, Nankai Tianjin China
| | - Changxiao Liu
- Shenyang Pharmaceutical University No. 103 Wenhua Road, Shenhe District Shenyang City Liaoning Province China +86-22-23006860 +86-22-23006860
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research 308, Anshan West Road, Nankai Tianjin China
| |
Collapse
|
16
|
He Y, Wei Z, Ci X, Xie Y, Yi X, Zeng Y, Li Y, Liu C. Effects of liquorice on pharmacokinetics of aconitine in rats. Xenobiotica 2019; 49:1485-1493. [DOI: 10.1080/00498254.2019.1579007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Yufei He
- Shenyang Pharmaceutical University, Shenyang, PR China
| | - Zihong Wei
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, PR China
- Tianjin Institute of Pharmaceutical Research, New Drug Assessment Co. Ltd, Tianjin, PR China
| | - Xiaoyan Ci
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, PR China
- Tianjin Institute of Pharmaceutical Research, New Drug Assessment Co. Ltd, Tianjin, PR China
| | - Ying Xie
- State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, PR China
| | - Xiulin Yi
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, PR China
- Tianjin Institute of Pharmaceutical Research, New Drug Assessment Co. Ltd, Tianjin, PR China
| | - Yong Zeng
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, PR China
- Tianjin Institute of Pharmaceutical Research, New Drug Assessment Co. Ltd, Tianjin, PR China
| | - Yazhuo Li
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, PR China
- Tianjin Institute of Pharmaceutical Research, New Drug Assessment Co. Ltd, Tianjin, PR China
| | - Changxiao Liu
- Shenyang Pharmaceutical University, Shenyang, PR China
- State Key Laboratory of Drug Delivery Technologies and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin, PR China
| |
Collapse
|
17
|
Lv QQ, Yang XN, Yan DM, Liang WQ, Liu HN, Yang XW, Li F. Metabolic profiling of dehydrodiisoeugenol using xenobiotic metabolomics. J Pharm Biomed Anal 2017; 145:725-733. [PMID: 28806569 DOI: 10.1016/j.jpba.2017.07.045] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 07/02/2017] [Accepted: 07/29/2017] [Indexed: 12/14/2022]
Abstract
Dehydrodiisoeugenol (DDIE), a representative and major benzofuran-type neolignan in Myristica fragrans Houtt., shows anti-inflammatory and anti-bacterial actions. In order to better understand its pharmacological properties, xenobiotic metabolomics was used to determine the metabolic map of DDIE and its influence on endogenous metabolites. Total thirteen metabolites of DDIE were identified through in vivo and in vitro metabolism, and seven of them were reported for the first time in the present study. The identity of DDIE metabolites was achieved by comparison of the MS/MS fragmentation pattern with DDIE using ultra-performance chromatography electrospray ionization quadrupole time-of-flight mass spectrometry (UPLC-ESI- QTOFMS). Demethylation and ring-opening reaction were the major metabolic pathways for in vivo metabolism of DDIE. Recombinant cytochrome P450s (CYPs) screening revealed that CYP1A1 is a primary enzyme contributing to the formation of metabolites D1-D4. More importantly, the levels of two endogenous metabolites 2,8-dihydroxyquinoline and its glucuronide were significantly elevated in mouse urine after DDIE exposure, which explains in part its modulatory effects on gut microbiota. Taken together, these data contribute to the understanding of the disposition and pharmacological activities of DDIE in vivo.
Collapse
Affiliation(s)
- Qian-Qian Lv
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China; Research Center for Differentiation and Development of Basic Theory of Traditional Chinese Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, China
| | - Xiao-Nan Yang
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China
| | - Dong-Mei Yan
- School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, China
| | - Wei-Qing Liang
- Center for Medicinal Resources Research, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, 310007, China.
| | - Hong-Ning Liu
- Research Center for Differentiation and Development of Basic Theory of Traditional Chinese Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, China
| | - Xiu-Wei Yang
- School of Pharmaceutical Sciences, Peking University Health Science Center, Peking University, Beijing, 100191, China
| | - Fei Li
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China; Research Center for Differentiation and Development of Basic Theory of Traditional Chinese Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, China.
| |
Collapse
|